Merck said to weigh allergy therapy unit sale to trim debt
[LONDON] Merck KGaA is considering a sale of its allergy business as the German company seeks to reduce debt following the US$17 billion takeover of Sigma-Aldrich Corp., according to people with knowledge of the matter.
The business, known as Allergopharma, may fetch about 600 million euros (S$896 million) and could attract interest from drug companies and private-equity firms, the people said, asking not to be identified because the deliberations are private. The process is at an early stage and Merck could still decide against a sale, the people said.
Sigma-Aldrich is the company's biggest deal to date and will let Merck reduce its dependence on drugs after more than a decade of failing to develop a new one.
The Allergopharma business focuses on diagnosing allergies and treating them by training patients' immune systems to be less reactive to substances such as mold and pollen.
A representative for Merck declined to comment.
BLOOMBERG
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue